"The U.S. Food and Drug Administration announced its preliminary determination that partially hydrogenated oils (PHOs), the primary dietary source of artificial trans fat in processed foods, are not "generally recognized as safe" for use in food. "...
Plasma-Lyte 148 and 5% Dextrose Injection
Plasma-Lyte 148d5 Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Plasma-Lyte 148 and 5% Dextrose Injection (multiple electrolytes and dextrose injection, type 1) is a fluid and electrolyte replenishment and caloric supply used as a source of water, electrolytes, and calories or as an alkalinizing agent. Common side effects include fever, injection site reactions (infection, blood clotting, swelling), or increase in blood volume.
Plasma-Lyte 148 and 5% Dextrose is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations. Plasma-Lyte 148 and 5% Dextrose may interact with corticosteroids or corticotropin. Tell your doctor all medications and supplements you use. During pregnancy, Plasma-Lyte 148 and 5% Dextrose should be used only if prescribed. It is unknown if this drug is passes into breast milk. Consult your doctor before breastfeeding.
Our Plasma-Lyte 148 and 5% Dextrose Injection (multiple electrolytes and dextrose injection, type 1) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Plasma-Lyte 148d5 FDA Prescribing Information: Side Effects
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.
Read the entire FDA prescribing information for Plasma-Lyte 148d5 (Multiple Electrolytes and Dextrose Injection)
Additional Plasma-Lyte 148 and 5% Dextrose Injection Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Weight Loss Wisdom
Get tips, recipes and inspiration.